Publications by authors named "Mary Horowitz"

Claim this Profile
P
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.
Stephanie J Lee, Brent Logan, Mary M Horowitz, Jason G Dehn, Joseph Pidala

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.
Jason G Dehn, Brent Logan, Stephanie J Lee, Bronwen E Shaw, Steven Devine, Mary Horowitz

Transplant Cell Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.
Andrew S Artz, Brent R Logan, Wael Saber, Nancy Geller, Anna Bellach, Mary M Horowitz

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Mary M Horowitz

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.
Neel S Bhatt, Azra Borogovac, Yvonne A Efebera, Anna DeSalvo, Steven M Devine, Mary M Horowitz

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.
Mohamed L Sorror, Wael Saber, Brent Logan, Nancy Geller, Anna Bellach, Mary M Horowitz

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.
Sameem Abedin, Michael J Martens, Javier Bolaños-Meade, Monzr M Al Malki, Qinghua Lian, Mary M Horowitz

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies.
Paul J Bröckelmann, Edward R Scheffer Cliff, Gloria Iacoboni, Florian Simon, Mary M Horowitz

Lancet Haematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Mary M Horowitz

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accurate prediction of absolute prokaryotic abundance from DNA concentration.
Jakob Wirbel, Tessa M Andermann, Erin F Brooks, Lanya Evans, Adam Groth, Mary M Horowitz

Cell Rep Methods· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko, Mary M Horowitz

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.
Adetola A Kassim, Mark C Walters, Mary Eapen, Madoc Smith, Brent R Logan, Mary M Horowitz

NEJM Evid· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.
Steven J Siegel, Susan DeWolf, Joseph Schmalz, Wael Saber, Jiayi Dong, Mary Horowitz

medRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Representativeness of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Trial Participants.
Manmeet Kaur, Mary M Horowitz, Adam Mendizabal, Min Chen, Amy Foley

Transplant Cell Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to S. Fuji.
Mark J Levis, Mehdi Hamadani, Mary M Horowitz, Yi-Bin Chen,

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors.
Yoshiko Atsuta, Helen Baldomero, Daniel Neumann, Anna Sureda, Jakob D DeVos, Mary M Horowitz

Haematologica· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.
Betty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, Dina Elsouda, Mehdi Hamadani, Mary M Horowitz

Blood Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study.
Mary Eapen, Joseph H Antin, Jakub Tolar, Sally Arai, Mitchell E Horwitz, Mary M Horowitz

EClinicalMedicine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial.
Jason G Dehn, Brent Logan, Bronwen E Shaw, Steven Devine, Stefan O Ciurea, Mary Horowitz

medRxiv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario, Mary M Horowitz

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
Joshua A Hill, Michael J Martens, Jo-Anne H Young, Kavita Bhavsar, Jianqun Kou, Mary M Horowitz

Clin Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients.
Bronwen E Shaw, Kathryn E Flynn, Naya He, Rachel Cusatis, Anita D'Souza, Mary M Horowitz

Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .
Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh, Mary M Horowitz

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.
Mary Eapen, Jianqun Kou, Martin Andreansky, Monica Bhatia, Joel Brochstein, Mary M Horowitz

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Joshua A Hill, Michael J Martens, Jo-Anne H Young, Kavita Bhavsar, Jianqun Kou, Mary M Horowitz

medRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis